Fracture risk in HIV and the need for guidelines: the Probono-1 Trial by Peters, B et al.
POSTER PRESENTATION Open Access
Fracture risk in HIV and the need for guidelines:
the Probono-1 Trial
B Peters
1*, H Isohanni
1, S Tillet
1, F Ibrahim
2, G Hampson
3, FMK Williams
4, MEO Perry
1, A Duncan
1, A Wierzbicki
3
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
Purpose of study
Fragility fractures are a common and increasing cause of
morbidity and mortality in the general population; risk
factors for fractures are commoner in HIV . This study
aims to determine the prevalence and associations of
low bone mineral density (BMD) and high fracture risk
(FR) in an HIV cohort, suggest screening and manage-
ment guidelines.
Methods
A cross-sectional study of 223 randomly selected HIV-
infected outpatients was undertaken. Recruitment was
stratified by gender for age groups 30-39, 40-49 yrs and
≥50 yrs. Osteopenia and osteoporosis were diagnosed
according to the WHO criteria. Patients completed a
detailed questionnaire including combination HIV drugs
(cART) history, & a dual-energy X-ray absorptiometry
(DEXA) of Lumbar spine & Left Hip. Investigations
included serum Ca, phosphate, 25OH vit D, alkaline
phosphatase (Alk P) PTH, albumin, sex hormone bind-
ing globulin (SHBG), testosterone, CD4, HIV RNA.
BMD risk factors were recorded including previous frac-
tures, smoking, malabsorption, alcohol consumption,
BMI, chronic diseases, physical activity index and past
medication. FRAX score (10yr probability major frac-
tures), and remaining lifetime fracture probability
(RLFP) were calculated. Controls were from the Twin
Research Unit at Kings College London. Data were ana-
lysed using multivariate logistic regression.
Results
Demographics: 133(60%) were male, 106(48%) were
Caucasian, 71(33%) had AIDS at diagnosis. 190(85%)
were taking cART, of whom 50(26%) were on their first
line therapy. Osteoporosis/osteopenia were present in
13%/39% of males, 11%/29% females, and was approxi-
mately 2.4/3.0 fold greater than age-matched controls.
The overall mean 10 yr fracture risk was 3.16%. RLFP
exceeded 1.0 in 76% HIV patients, and <20% controls.
Factors associated with low BMD after multivariate ana-
lysis: adjusted OR(95 % CI)/p-value BMI 0.90(0.83,0.96),
p<0.001, Alk P 1.01(1.00,1.02), p 0.05, testosterone 1.04
(1.01,1.07), p 0.01, Initiated cART 3.61(1.38,9.42), p 0.01.
The lack of association with age is notable, adjusted OR
1.08(0.92,1.26), p 0.35.
Conclusions
Reduced bone mineral density and subsequent fracture
risk is much commoner in patients with HIV compared
to controls, especially, and those taking cART, and
occurred across the age ranges. Hence screening for
BMD and risk factors for fragility fractures is indicated
in patients with HIV at a younger age than in the gen-
eral population, especially if they are on cART.
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